SCHEMBL430063

SCHEMBL430063

C#Cc1ccc(OCc2ccncc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.54
F2 P00734 2/20 0.46
MAOB P27338 2/20 0.44
KCNH2 Q12809 1/20 0.44
GRIN2B Q13224 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
CYP27B1 O15528 1/20 0.43
CYP24A1 Q07973 1/20 0.43
NPC1 O15118 1/20 0.43
HTT P42858 1/20 0.43
APP P05067 1/20 0.42
EPHX2 P34913 1/20 0.41
CYP11B1 P15538 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
PTGS1 P23219 1/20 0.40
SLC6A2 P23975 1/20 0.40
CYP2C19 P33261 1/20 0.40
PTGS2 P35354 1/20 0.40
SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21115280 0.83 HDAC8 (0.56) HDAC8F2MAOBGRIN2BSMN1; SMN2
SCHEMBL227697 0.81 MAOB (0.67) MAOBSMN1; SMN2EPHX2LMNACYP1A2
SCHEMBL30150350 0.78 APP (0.62) MAOBSMN1; SMN2NPC1HTTAPP
SCHEMBL18639810 0.78 MAOB (0.68) MAOBAPPMAOA
SCHEMBL7078819 0.77 F2 (0.49) F2MAOBKCNH2GRIN2BSMN1; SMN2
SCHEMBL1825953 0.77 APP (0.73) HDAC8F2KCNH2GRIN2BAPP
SCHEMBL3182484 0.77 MAOB (0.66) F2MAOBKCNH2GRIN2BSMN1; SMN2
SCHEMBL6291457 0.77 F2 (0.49) F2MAOBKCNH2GRIN2BSMN1; SMN2
SCHEMBL18297574 0.77 APP (0.60) MAOBSMN1; SMN2NPC1APPEPHX2
SCHEMBL27037838 0.77 APP (0.61) F2MAOBKCNH2GRIN2BAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575150-B2 Triazole derivatives for treatment of Alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2013-11-05 US disclosed
US-8575150-B2 Triazole derivatives for treatment of Alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2013-11-05 US disclosed
US-8575150-B2 Triazole derivatives for treatment of Alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2013-11-05 US disclosed
US-20120022044-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2012-01-26 US disclosed
US-20120022044-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2012-01-26 US disclosed
US-20120022044-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2012-01-26 US disclosed
EP-2378879-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE Merck Sharp & Dohme Corp. (US) 2011-10-26 EP disclosed
WO-2010071741-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME CORP. (US) 2010-06-24 WO disclosed
WO-2010071741-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME CORP. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022044-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MAPT, BACE1, APP HDAC8 367/4885F2 4172/4885MAOB 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.